MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies ...
PhaseBio had already shown its Brilinta reversal agent could work in healthy volunteers, but now the biotech has the phase 3 data to back up the therapy's use in patients who are in an emergency ...
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today ...
MALVERN, Pa. and SAN DIEGO, Sept. 24, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and ...
-First clinical evaluation of BB-025, designed to rapidly and specifically reverse BB-031 activity, advancing Basking's goal to redefine thrombosis treatment- RESEARCH TRIANGLE, N.C., Nov. 12, 2025 ...
Global Phase 3 trial of bentracimab achieved primary reversal endpoint with immediate and sustained reversal of the antiplatelet effects of ticagrelor in both surgical and bleeding populations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback